Compare OFG & CAPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | OFG | CAPR |
|---|---|---|
| Founded | 1964 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.3B |
| IPO Year | 2012 | 2011 |
| Metric | OFG | CAPR |
|---|---|---|
| Price | $38.68 | $30.62 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 8 |
| Target Price | $43.40 | ★ $44.63 |
| AVG Volume (30 Days) | 271.5K | ★ 1.2M |
| Earning Date | 04-22-2026 | 03-12-2026 |
| Dividend Yield | ★ 3.62% | N/A |
| EPS Growth | ★ 8.27 | N/A |
| EPS | ★ 4.58 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $10.14 | N/A |
| Revenue Next Year | $1.38 | $31.86 |
| P/E Ratio | $8.45 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $33.15 | $4.30 |
| 52 Week High | $46.11 | $40.37 |
| Indicator | OFG | CAPR |
|---|---|---|
| Relative Strength Index (RSI) | 35.82 | 58.59 |
| Support Level | $37.79 | $25.33 |
| Resistance Level | $43.03 | $36.49 |
| Average True Range (ATR) | 1.03 | 2.03 |
| MACD | -0.15 | 0.12 |
| Stochastic Oscillator | 25.96 | 49.96 |
OFG Bancorp is a financial holding company, through its subsidiaries provides banking and financial services. It operates through three segments namely Banking, Wealth Management, and Treasury. It serves to clients such as commercial, consumer, auto, and mortgage lending, checking and savings accounts, financial planning, insurance, financial services, and investment brokerage, and corporate and individual trust and retirement services. The company derives maximum revenue from Banking Segment. It provides services in the region of Puerto Rico.
Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.